Last reviewed · How we verify
NCT05981066
A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma
NA trial testing Neoantigen vaccine, I.M injection in Advanced Hepatocellular Carcinoma in 48 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 10 July 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neoantigen vaccine, I.M injection — full drug profile →
Conditions studied
- Advanced Hepatocellular Carcinoma — all drugs for Advanced Hepatocellular Carcinoma →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label, single-site, investigator-initiated trial designed to evaluate the safety, tolerability and preliminary efficacy of ABOR2014(IPM511) injection in relapsed/ refactory HCC.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in mRNA-Based Cancer Vaccines.
Ni L. · · 2023 · cited 33× · PMID 37897001 · DOI 10.3390/vaccines11101599 -
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines.
Lin F, Lin EZ, Anekoji M, Ichim TE, et al · · 2023 · cited 22× · PMID 37978542 · DOI 10.1186/s12967-023-04724-0 -
The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases.
Deyhimfar R, Izady M, Shoghi M, Kazazi MH, et al · · 2024 · cited 17× · PMID 38486748 · DOI 10.1016/j.heliyon.2024.e26971 -
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy.
Shariati A, Khani P, Nasri F, Afkhami H, et al · · 2024 · cited 16× · PMID 39696625 · DOI 10.1186/s40364-024-00692-9 -
Leveraging mRNA technology for antigen based immuno-oncology therapies.
Floudas CS, Sarkizova S, Ceccarelli M, Zheng W. · · 2025 · cited 11× · PMID 39848687 · DOI 10.1136/jitc-2024-010569 -
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.
Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, et al · · 2024 · cited 9× · PMID 39399167 · DOI 10.3389/fonc.2024.1454370 -
Artificial Intelligence-Driven Strategies for Targeted Delivery and Enhanced Stability of RNA-Based Lipid Nanoparticle Cancer Vaccines.
Bhujel R, Enkmann V, Burgstaller H, Maharjan R. · · 2025 · cited 8× · PMID 40871015 · DOI 10.3390/pharmaceutics17080992 -
Nanotechnology for immuno-oncology.
Grippin AJ, Lee D, Parkes EE, Jiang W, et al · · 2025 · cited 7× · PMID 40775548 · DOI 10.1038/s43018-025-01025-x
Verify or expand the search:
- PubMed search for NCT05981066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06811116 — Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta · Phase 1, PHASE2 · recruiting
- NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05981066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 8 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05981066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing